32
Georg Noll HerzKlinik Hirslanden Update Lipide Diabetes [email protected] / georg.noll@hirslanden.ch

Update Lipide Diabetes Herbsttagung 2013_Georg N… · Georg Noll HerzKlinik Hirslanden Update Lipide Diabetes [email protected] / [email protected]

Embed Size (px)

Citation preview

Georg Noll HerzKlinik Hirslanden

Update Lipide Diabetes

[email protected] / [email protected]

Effects of Mediterranean Diet���on AMI, Stroke, and CV Death

Estruch R et al: NEJM 2013 (PREDIMED)

Age: 67 y BMI: 30 DM: 48% HT: 82%

n–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction

Alpha Omega Trial

Kromhout D et al: NEJM 2010

Dietary linoleic acid for secondary prevention of CAD ���Sydney Diet Heart Study

Ramsden CE et al: BMJ 2013

PUFAs for secondary prevention of CV death ���Metaanalysis

Ramsden CE et al: BMJ 2013

7

Chocolate Consumption and Nobel Prizes

Messerli F: NEJM 2012

Dal Moro F: Maturitas 2013

Coffee Consumption and Nobel Prizes

1 mmol/L LDL-Reduction is associated with…..

CTT Collaborators. Lancet 2005

LDL-Reduction with statins and vascular events

50

40

30

20

10

0 0.5 1.0 1.5 2.0

-10 LDL-Reduction in mmol/L

50

40

30

20

10

-10

0 0.5 1.0 1.5 2.0

LDL-Reduction in mmol/L

Prospective metaanalysis of 90,056 patients from 14 studies1

…. 23% Reduction of coronary events

…. 21% Reduction of vascular events

Pro

prtio

nal r

educ

tion

of

eve

nts

(%±S

E)

Pro

porti

onal

redu

ctio

n

of e

vent

s (%

±SE

)

Adapted from Rosensen RS. Exp Opin Emerg Drugs 2004;9(2):269-279

LDL-C achieved mg/dL (mmol/L)

WOSCOPS – Placebo AFCAPS - Placebo

ASCOT - Placebo AFCAPS - Rx WOSCOPS - Rx

ASCOT - Rx

4S - Rx

HPS - Placebo

LIPID - Rx

4S - Placebo

CARE - Rx

LIPID - Placebo

CARE - Placebo

HPS - Rx

0

5

10

15

20

25

30

40 (1.0)

60 (1.6)

80 (2.1)

100 (2.6)

120 (3.1)

140 (3.6)

160 (4.1)

180 (4.7)

Eve

nt ra

te (%

)

6

Secondary Prevention

Primary Prevention

Rx - Statin therapy PRA – pravastatin ATV - atorvastatin

200 (5.2)

PROVE-IT - PRA

PROVE-IT – ATV

TNT – ATV10 TNT – ATV80

The lower the better!

JUPITER - Pl

JUPITER - Rx

POSCH

POSCH

Works in everybody except heart failure

EMPFEHLUNGEN NACH IAS 2003 modifiziert und aktualisiert für die Schweiz 2012

EAS/ESC EMPFEHLUNGEN 2011

EAS/ESC EMPFEHLUNGEN 2011

EMPFEHLUNGEN NACH IAS 2003 modifiziert und aktualisiert für die Schweiz 2012

Medikamentöse Behandlung der Dyslipidämie

Effects of PCSK9 Antibody on LDL

Lancet 2012

Effects of PCSK9 Antibody on top of Statins on LDL

Lancet 2012

Effects of a monoclonal antibody to PCSK9, REGN727 on LDL in familial hypercholesterolaemia on statin dose +/- ezetimibe

Stein EA et al: Lancet 2012

(n=15) (n=15) (n=16)

(n=16) (n=15)

LDL 3.6 - 4.4 mmol/l

71% on ezetimibe, 42% CAD

(≥4.9 mmol/l)

AHA Guideline on the Treatment of Blood Cholesterol���to Reduce Atherosclerotic Cardiovascular Risk

Stone NJ et al: Circulation 2013

(1.8-4.9 mmol/l)

LDL <4.9 mmol/l

Stone NJ et al: Circulation 2013

Intensity of Statin Therapy

Stone NJ et al: Circulation 2013

Statins an New Onset of Diabetes

Sattar N et al: Lancet 2010

CV Benefit > Risk of diabetes (9:1)

9 CV events prevented vs

1 case of diabetes

By treating for 4 years 255 patients with a

standard dose of statins

Adapté de Sattar et al. Lancet 2010; 375: 735-42. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.

Hohe Triglyzeride (>2.3 mmol/l) Tiefes HDL (<0.9 mmol/l)

Normale Triglyzeride Normales HDL (<0.9 mmol/l)

Studien mit Fibraten - Odds Ratio für ein koronares Ereignis ist abhängig von den Ausgangs-Lipidwerten

Sacks et al: NEJM 2010

Therapie der arteriellen Hypertonie

RAS-Blocker

Effects of intensive Blood Pressure Control in Diabetics ACCORD

NEJM 2010

Goal <140 mmHg

Goal <120 mmHg

BP: 139 -> 134

BP: 139 -> 119

Effects of Intensive vs Standard BP Control on Stroke MI, and CV Death in Type II Diabetes (ACCORD)

NEJM 2010

Messerli, F. H. et al. J Am Coll Cardiol 2009;54:1827-1834

Incidence of MI and Stroke Stratified by Diastolic Blood Pressure in the INVEST Study

Aged under 55 years

Aged over 55 years or black person of African or

Caribbean origin of any age

A C

A + C

A + C + D

Resistant hypertension consider further diuretic

alpha or betablocker consider seeking expert advise

Step 1

Step 2

Step 3

Step 4

A=ACEI or ARB C=CCB D=Thiazide diuretic

NICE 2011

ESH: Zielwert für alle <140/90 mmg ausser Diabetiker <140/85 mmHg

Long-term Effect of Renal nerve Denervation on Blood Pressure in Resistant Hypertension

p <0,01 für Δ gegenüber der Baseline für alle Zeitpunkte

Effects of Renal Denervation on Office BP (Zurich Experience, N= 36)

Effects of Renal Denervation on ABPM (Zurich Experience, N= 36)

Take home messages

• Diät wirkt v.a. primärpräventiv

• Cholesterin ist ein behandelbarer Risikofaktor

• Hochrisikopatienten aggressiv behandeln (Zielwerte?)

• Grenzen der Statine: Herzinsuffizienz.

• Zur Senkung der Triglyzeride: Fibrat

• Blutdruckzielwert bei Hypertonie: <140/90 mmHg ausser: Betagte: <150/90 mmHg Diabetiker: <140/85 mmHg

• Bei resistenter Hypertonie renale Denervation erwägen